v3.25.3

Consolidated Balance Sheets - USD ($)	Sep. 30, 2025	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 409,000	$ 86,128	$ 170,405
Restricted cash	20,000	20,000	20,000
Accounts receivable	3,976	18,976	18,976
Prepaid & other current assets	1,179,972	9,107	62,356
Total current assets	1,612,948	134,211	271,737
In process R&D	1,101,760	1,101,760	1,101,760
Goodwill, net	2,788,230	2,788,230	5,988,230
Investment in GMP Bio at fair value	22,653,225	22,653,225	22,653,225
Total assets	28,156,163	26,677,426	30,014,952
Current liabilities:
Accounts payable and accrued liabilities	2,565,877	2,437,167	2,437,321
Contingent Consideration	2,625,000	2,625,000	2,625,000
Derivative liability on notes	670,844	703,616	423,214
Total current liabilities	20,079,663	19,199,914	16,504,947
Convertible long-term debt, net of costs			1,898,468
Total liabilities	20,079,663	19,199,914	18,403,415
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $.01 par value; 750,000,000 shares authorized; 407,289,618 and 399,184,128 issued and outstanding, respectively	4,394,463	4,072,899	3,991,839
Additional paid-in capital	43,765,008	42,219,400	41,655,026
Accumulated deficit	(39,108,893)	(38,040,668)	(33,516,736)
Total Oncotelic Therapeutics, Inc. stockholders’ equity	9,050,578	8,251,631	12,130,129
Non-controlling interests	(974,078)	(774,119)	(518,592)
Total stockholders’ equity	8,076,500	7,477,512	11,611,537
Total liabilities and stockholders’ equity	28,156,163	26,677,426	30,014,952
Related Party [Member]
Current liabilities:
Accounts payable - related party	347,598	346,057	344,099
Convertible debt and short-term debt, net of costs	3,542,244	3,297,208	2,608,356
Nonrelated Party [Member]
Current liabilities:
Convertible debt and short-term debt, net of costs	$ 10,328,100	$ 9,790,866	$ 8,066,957

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

Oncotelic Therapeutics, Inc. S-1